Apexigen, Inc. transaction expected close, later in August 2023; Anticipated Yale presentation of investigator sponsored trial results describing an anti-siglec-15 compound’s activity and safety at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, September 2023; Announce clinical development plan for sotigalimab, Q4 2023; Report pharmacokinetic/pharmacodynamic data for sotigalimab, Q4 2023; Report preliminary data, including biomarker results and early signs of potential clinical activity from PYX-106-101, late 2023; Report preliminary data, including biomarker results and early signs of potential clinical activity from PYX-201-101, early 2024
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PYXS:
- PYXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
- Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
- Pyxis Oncology initiated with a Buy at EF Hutton
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Questions or Comments about the article? Write to editor@tipranks.com